News Article

At the end of September, CytoReason held its CytoSummit employee conference on the beautiful island of Crete. The focus was on how to improve the probability of success in phase 2 clinical trials.

Candesic Managing Partner Dr Leonid Shapiro was amongst the experts asked to provide insights into CytoReason’s market and competitive positioning, the biotech industry and AI’s growing role in drug development.

Leonid spoke alongside other notable speakers including Parker Moss from Exscientia, David Ruau from NVIDIA, Yair Benita from AION Labs and Marie Lübkert from Nomura.